Press Release: Umecrine Cognition : Karolinska Development's portfolio company Umecrine Cognition submits a Clinical Trial Application to initiate a phase 2 clinical trial with golexanolone

STOCKHOLM, SWEDEN May 19, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has submitted a clinical trial application (CTA) to the Hungarian regulatory body OGÝEI for approval to initiate...